AU2001269923A1 - Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases - Google Patents

Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Info

Publication number
AU2001269923A1
AU2001269923A1 AU2001269923A AU6992301A AU2001269923A1 AU 2001269923 A1 AU2001269923 A1 AU 2001269923A1 AU 2001269923 A AU2001269923 A AU 2001269923A AU 6992301 A AU6992301 A AU 6992301A AU 2001269923 A1 AU2001269923 A1 AU 2001269923A1
Authority
AU
Australia
Prior art keywords
therapy
small molecule
lysosomal storage
storage diseases
enzyme replacement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269923A
Inventor
Seng H Cheng
David Meeker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2001269923A1 publication Critical patent/AU2001269923A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2001269923A 2000-06-19 2001-06-19 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases Abandoned AU2001269923A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21237700P 2000-06-19 2000-06-19
US60/212,377 2000-06-19
PCT/US2001/019579 WO2001097829A2 (en) 2000-06-19 2001-06-19 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Publications (1)

Publication Number Publication Date
AU2001269923A1 true AU2001269923A1 (en) 2002-01-02

Family

ID=22790749

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269923A Abandoned AU2001269923A1 (en) 2000-06-19 2001-06-19 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Country Status (3)

Country Link
US (4) US20020095135A1 (en)
AU (1) AU2001269923A1 (en)
WO (1) WO2001097829A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
DE60138535D1 (en) * 2000-02-04 2009-06-10 Children S Hospital Res Founda USE OF LYSOSOMAL ACID LIPASE FOR THE TREATMENT OF ATHEROSCLEROSIS AND SIMILAR DISEASES
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US20020142299A1 (en) * 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
AU2002241853A1 (en) * 2001-01-12 2002-07-24 Oxford Glycosciences (Uk) Ltd. Mucopolysaccharidosis therapies
US8241622B2 (en) * 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
EP1336411A1 (en) * 2002-02-14 2003-08-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
US20030223966A1 (en) * 2002-04-30 2003-12-04 Fraites Thomas J. Treatment for pompe disease
WO2004055157A2 (en) * 2002-08-13 2004-07-01 Whitley Chester B Methods of using vectors to treat metabolic disorders
ES2541785T3 (en) * 2003-01-31 2015-07-24 The Mount Sinai School Of Medicine Of New York University Combination therapy to treat protein deficiency disorders
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
US9181184B2 (en) * 2005-05-17 2015-11-10 Amicus Therapeutics, Inc. Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
WO2007030375A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
SI1973561T1 (en) * 2005-12-15 2011-07-29 Chemgen Corp Enzymes for reduced immunological stress
ES2391657T3 (en) 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Stabilized protein compositions that have a free thiol moiety
CA2706727A1 (en) 2007-11-29 2009-06-11 Michael S. Mcgrath Compositions and methods for treating lysosomal disorders
EP2271213A4 (en) * 2008-02-01 2011-06-29 Scripps Research Inst Methods for treating a condition characterized by dysfunction in protein homeostasis
JP2011512876A (en) * 2008-03-12 2011-04-28 アミカス セラピューティックス インコーポレイテッド Treatment of Pompe disease with specific pharmacological chaperones and monitoring of treatment with surrogate markers
PT2484371E (en) 2008-06-26 2015-03-03 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
BR122020010601B8 (en) 2008-12-16 2021-07-27 Genzyme Corp protein-oligosaccharide conjugates, their uses, and pharmaceutical compositions
CA2793276A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
CN105126086B (en) * 2009-07-28 2019-05-14 夏尔人类遗传性治疗公司 For treating the composition and method of Gaucher disease
EP2470199B1 (en) * 2009-08-28 2019-05-22 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
JP5739898B2 (en) * 2009-11-17 2015-06-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Urinary triosylceramide (GB3) as a heart disease marker
US8765698B2 (en) * 2010-02-03 2014-07-01 University Of Central Florida Research Foundation, Inc. Methods and products for reawakening retrocyclins
ES2950358T3 (en) 2010-04-23 2023-10-09 Alexion Pharma Inc Lysosomal storage disease enzyme
WO2012012461A2 (en) 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
EP3650039A1 (en) 2010-09-09 2020-05-13 Alexion Pharmaceuticals, Inc. Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
ES2753169T3 (en) 2010-11-30 2020-04-07 Orphazyme As Procedures to increase intracellular activity of Hsp70
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
WO2012112677A2 (en) * 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
US9265815B2 (en) 2011-04-29 2016-02-23 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers
CN103764824B (en) 2011-06-20 2018-04-24 西奈山医学院 The anti-tnf-alpha therapy of mucopolysaccharidosis and other lysosome illnesss
KR20140138850A (en) 2012-03-02 2014-12-04 샤이어 휴먼 지네틱 테라피즈 인크. Compositions and methods for treating type iii gaucher disease
KR20230066482A (en) 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 High concentration alpha-glucosidase compositions for the treatment of pompe disease
PL2844279T3 (en) 2012-05-03 2021-08-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
US9694056B2 (en) 2012-07-17 2017-07-04 Amicus Therapeutics, Inc. α-galactosidase A and 1-deoxygalactonojirimycin co-formulation
SG11201502989XA (en) 2012-11-05 2015-05-28 Genzyme Corp Compositions and methods for treating proteinopathies
JP7028556B2 (en) 2013-05-03 2022-03-02 セレクタ バイオサイエンシーズ インコーポレーテッド Delivery of immunosuppressive agents with antigens for specific pharmacodynamic efficacy and induction of immune tolerance
MX2017002933A (en) 2014-09-07 2017-05-30 Selecta Biosciences Inc Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses.
BR112017004948A2 (en) 2014-09-15 2017-12-05 Orphazyme Aps pharmaceutical formulation.
SG11201702114TA (en) 2014-09-30 2017-04-27 Amicus Therapeutics Inc Highly potent acid alpha-glucosidase with enhanced carbohydrates
HRP20230468T1 (en) * 2014-12-22 2023-11-10 Codexis, Inc. Human alpha-galactosidase variants
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MY198085A (en) 2015-12-30 2023-07-31 Amicus Therapeutics Inc Augmented acid alpha-glucosidase for the treatment of pompe disease
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
EP3426787A1 (en) 2016-03-07 2019-01-16 University of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
MX2018011679A (en) * 2016-03-25 2019-06-24 Genzyme Corp Biomarkers of proteopathies and uses thereof.
WO2017173059A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
CA3019128A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
RU2750154C2 (en) 2016-04-29 2021-06-22 Орфазим А/С Arimoclomol for treatment of glucocerebrosidase-associated disorders
CN109152342A (en) * 2016-05-12 2019-01-04 布赖恩.P.汉利 CRISPR and most of body cell of other gene therapy safe deliveries into human and animal
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
BR112019002719A2 (en) * 2016-08-11 2019-05-14 Intrabio Ltd acetyl leucine, or a pharmaceutically acceptable salt thereof, for use in methods related to lysosomal deposition diseases
EP3509628A1 (en) * 2016-09-09 2019-07-17 Fondazione Telethon Combined therapy for mucopolysaccharidosis type vi (maroteaux-lamy-syndrome)
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
BR112019025888A2 (en) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polynucleotide encoding a therapeutic multi-domain protein, gene therapy vector, recombinant multi-domain therapeutic protein, expression method, methods to reduce the accumulation of glycogen in a tissue in a patient in need, to reduce the accumulation of glycogen in a tissue in a patient in need and to treat enzyme deficiency in a patient in need and / or tolerate the patient to the enzyme for which he is deficient, anti-cd63 antibody or antigen binding fragment, and pharmaceutical composition
EP3823590A4 (en) * 2018-07-18 2022-04-20 REGENXBIO Inc. Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idus)
CA3202568A1 (en) 2020-11-19 2022-05-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
WO2023164060A2 (en) * 2022-02-25 2023-08-31 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5236938A (en) * 1991-04-30 1993-08-17 Rhone-Poulenc Inc. Pesticidal 1-aryl-5-(substituted alkylideneimino)pyrazoles
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5834266A (en) * 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5836905A (en) 1994-06-20 1998-11-17 Lemelson; Jerome H. Apparatus and methods for gene therapy
US5910487A (en) 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5747471A (en) 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
AU715543B2 (en) 1995-09-08 2000-02-03 Genzyme Corporation Improved AAV vectors for gene therapy
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5840702A (en) 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
US5935936A (en) 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US6177447B1 (en) * 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
EP1538202B1 (en) 1996-09-13 2014-01-22 Shire Human Genetic Therapies, Inc. Production of human alpha-galactosidase A
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US5925628A (en) 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5942634A (en) 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP2147681A1 (en) * 1997-10-29 2010-01-27 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
EP1056880A1 (en) 1998-02-17 2000-12-06 Genzyme Corporation Methods for purified aav vector production
WO1999041400A1 (en) 1998-02-17 1999-08-19 Genzyme Corporation Methods for pseudoadenoviral vector production
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9909066D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
WO2001007078A1 (en) 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
ES2284545T3 (en) 1999-11-16 2007-11-16 Genzyme Corporation VECTORS AND TRANSGINS WITH REGULATING ELEMENTS FOR THE ADMINISTRATION OF LIVER GENES.
WO2001060377A2 (en) * 2000-02-17 2001-08-23 Genzyme Corporation Methods for treatment of lysosomal storage diseases using biphosphonates
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
ES2541785T3 (en) 2003-01-31 2015-07-24 The Mount Sinai School Of Medicine Of New York University Combination therapy to treat protein deficiency disorders

Also Published As

Publication number Publication date
WO2001097829A2 (en) 2001-12-27
US7910545B2 (en) 2011-03-22
WO2001097829A3 (en) 2002-12-27
US20070280925A1 (en) 2007-12-06
US8168587B2 (en) 2012-05-01
US20110142818A1 (en) 2011-06-16
US20120183502A1 (en) 2012-07-19
US20020095135A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
AU2001269923A1 (en) Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
EP1463512A4 (en) Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
AU2001280767A1 (en) Peptide-mediated delivery of molecules into cells
AU1878601A (en) Enzyme
AU3818300A (en) Treating hair by targeting enzymes
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2001245822A1 (en) Fungal lactate dehydrogenase gene and constructs for the expression thereof
AU2001227900A1 (en) Drug metabolizing enzymes
AU2001274981A1 (en) Drug metabolizing enzymes
AU2001236713A1 (en) Methods for treatment of lysosomal storage diseases
AUPQ262599A0 (en) Gene expression
AU2001270303A1 (en) Drug metabolizing enzymes
AU4009899A (en) Molecules targeting cd40 and tumor cells
AUPR311601A0 (en) Matrix gene expression in chondrogenesis
AU2001265096A1 (en) Short-root gene, promoter, and uses thereof
AU2001270478A1 (en) Gene expression in biological conditions
AU7709300A (en) Drug discovery using gene expression profiling
AU2732000A (en) Reverse gene therapy
AU1194201A (en) Fluorotellurite, amplifier glasses
AU2153401A (en) Gene expression in biological conditions
AU2001255324A1 (en) Drug metabolizing enzymes
AU2001235000A1 (en) Drug metabolizing enzymes
AU2001247444A1 (en) Erbeta-mediated gene expression
AU2001278154A1 (en) Drug metabolizing enzymes
AU2352301A (en) Gene expression in corneal diseases